Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson TECVAYLI (teclistamab) by Year
TECVAYLI (teclistamab) — Worldwide operational (constant-currency) growth YoY (%) (%)
Johnson & Johnson TECVAYLI (teclistamab): 21.5% in FY2025, down 18.3 pts from a year earlier.
Where the FY2025 figure comes from
“|| WW | 670 | 549 | 22.1 | 21.5 | 0.6”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TECVAYLI (teclistamab) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 21.5% | -18.3 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 39.8% | – | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
Breakdown
What makes up TECVAYLI (teclistamab)
Cite this data
StockData. (2026). Johnson & Johnson TECVAYLI (teclistamab) (%), annual FY2024–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-tecvayli-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.